JHL Biotech Reports Dosing of its First Patient with JHL1266 (biosimilar, denosumab) in P-I Study in Australia
JHL Biotech’s Trastuzumab Biosimilar (JHL1188) Receives CHMP Positive Scientific Advice to Treat Breast Cancer
Shots:
- The study involves assessing of JHL1266 vs Prolia sourced from the EU and the US in healthy human subjects evaluating its PK, PD, and immunogenicity
- The JHL1266 is proved to be a milestone and an initiative in bringing safe, effective, and high-quality biologics
- JHL1266 is a mAb targeting RANKL works by inhibition of developed osteoclasts and then preventing break down of bones in the human body and is targeted for osteoporosis, bone metastases, giant cell tumors of bone, and other treatment-induced bone loss
Click here to read full press release/ article | Ref: JHL | Image: Behance